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COVID-19 outbreak, caused by severe acute respiratory syndrome (SARS)-CoV-2
coronavirus has become an urgent health and economic challenge. Diabetes is a risk
factor for severity and mortality of COVID-19. Recent studies support that COVID-19 has
effects beyond the respiratory tract, with vascular complications arising as relevant factors
worsening its prognosis, then making patients with previous vascular disease more prone
to severity or fatal outcome. Angiotensin-II converting enzime-2 (ACE2) has been
proposed as preferred receptor for SARS-CoV-2 host infection, yet specific proteins
participating in the virus entry are not fully known. SARS-CoV-2 might use other co-
receptor or auxiliary proteins allowing virus infection. In silico experiments proposed that
SARS-CoV-2 might bind dipeptidyl peptidase 4 (DPP4/CD26), which was established
previously as receptor for MERS-CoV. The renin–angiotensin–aldosterone system (RAAS)
component ACE2 and DPP4 are proteins dysregulated in diabetes. Imbalance of the
RAAS and direct effect of soluble DPP4 exert deleterious vascular effects. We hypothesize
that diabetic patients might be more affected by COVID-19 due to increased presence
ACE2 and DPP4 mediating infection and contributing to a compromised vasculature.
Here, we discuss the role of ACE2 and DPP4 as relevant factors linking the risk of SARS-
CoV-2 infection and severity of COVID-19 in diabetic patients and present an outlook on
therapeutic potential of current drugs targeted against RAAS and DPP4 to treat or prevent
COVID-19-derived vascular complications. Diabetes affects more than 400 million people
worldwide, thus better understanding of how they are affected by COVID-19 holds an
important benefit to fight against this disease with pandemic proportions.
Keywords: COVID-19, SARS-CoV-2, diabetes, cardiovascular disease, angiotensin converting enzyme 2, dipeptidyl
peptidase 4, gliptins, ACEiin.org August 2020 | Volume 11 | Article 11611
GRAPHICAL ABSTRACT | Patients with obesity, T2DM or CV comorbidities display an imbalance in the RAAS system and upregulated sDPP4 levels. These 2
factors per se increase the risk for bronchoconstriction, lung inflammation, heart failure, endothelial dysfunction, atherosclerosis and immune dysregulation. ACE2 is a
receptor for SARS-CoV-2 and DPP4 has been poposed as potential co/receptor. We hypothesize that in patients with these comorbidities, where both ACE2 and
sDPP4 are enhanced, infection with SARS-CoV-2 may result in increased COVID-19 severity with pulmonar complications such as ALI, ARDS and CV complications
such as heart failure, arrhythmia, myocarditis, endothelitis, oedema and coagulopathy.
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Diabetes as Promoter of Severity and
Mortality in COVID-19
The recent outbreak of COVID-19 pneumonia in China (Guan
et al., 2020; Huang et al., 2020) has become an urgent health and
economic challenge due to its pandemic proportions. Therefore,
there is a current race for developing strategies to treat or prevent
COVID-19 infection. COVID-19 is caused by the new severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
During the last 20 years other two betacoronaviruses bursted,
namely SARS-CoV and middle east respiratory syndrome
(MERS)-CoV, yet without such pandemic impact.
Similarly to former influenza infections, there is increasing
evidence that diabetes is an important risk factor for the severity
and mortality of COVID-19 (Hill et al., 2020; Klonoff and
Umpierrez, 2020; Zhou et al., 2020). A meta-analysis pointed
towards hypertension and cardiovascular (CV) disease and
diabetes as the most prevalent cardiometabolic comorbiditiesAbbreviations: ACE2, angiotensin converting enzyme 2; ACEi, angiotensin
converting enzyme 2 inhibitors; ALI, acute lung injury; Ang II, angiotensin II;
Ang-(1-7), angiotensin-(1-7); ARB, angiotensin receptor 1 blockers; ARDS, acute
respiratory distress syndrome; AT, anti-thrombin; ATR1, angiotensin receptor 1;
ATR2, angiotensin receptor 2; BNP, brain natriuretic peptide; CCL5, chemokine
(C-C Motif) ligand 5; COVID-19, coronavirus disease-19; CRP, C-reactive
protein; CV, cardiovascular; DPP4, dipeptidyl peptidase 4; DPP4i, dipeptidyl
peptidase 4 inhibitors; GIP, gastric inhibitory peptide; GLP-1, glucagon-like
peptide-1; IL, interleukin; ICU, intensive care unit; LDLR, low-density-
lipoprotein receptor; MERS, Middle East respiratory syndrome; Mrc1,
macrophage mannose receptor 1; NO, nitric oxide; NT-pro-BNP, N-terminal
pro-brain natriuretic peptide; PT, pro-thrombin; RAAS, renin-angiotensin
aldosterone system; RANTES, regulated upon activation, normal T cell
expressed and presumably secreted; RBD, receptor binding domain; SARS-CoV-
2, severe acute respiratory syndrome coronavirus-2; STZ, streptozotocin; rhACE2,
recombinant human angiotensin converting enzyme 2; sDPP4, soluble dipeptidyl
peptidase 4; T2DM, type 2 diabetes mellitus; TnT, troponin T; VCAM-1, vascular
cell adhesion molecule-1.
Frontiers in Pharmacology | www.frontiersin.org 2in COVID-19 hospitalized patients (Li B. et al., 2020). The first
large cohort of hospitalized patients with COVID-19 in Europe
confirmed arterial hypertension, followed by chronic heart
disease and diabetes as the main comorbidities upon
hospitalisation. While at intensive care unit (ICU) the most
frequent comorbidities were hypertension, obesity and diabetes
(Borobia, 2020; Vaduganathan et al., 2020). Furthermore, recent
studies suggest that obesity may be related to increased COVID-
19 severity (Petrilli et al., 2020; Simonnet et al., 2020) even in
younger patients (Lighter et al., 2020).
Being CV diseases the main cause of morbi-mortality in type
2 diabetic patients, it is not surprising that besides being
comorbidities, obesity, type 2 diabetes mellitus (T2DM) and
CV diseases have been suggested as risk factors for severity in
COVID-19 in several meta-analysis (Wang B. et al., 2020;
Zhang D. et al., 2020). In fact, in a retrospective cohort study
including 72.314 COVID-19 patients, those with previous CV
comorbidities displayed five-fold higher mortality risk (Wu and
McGoogan, 2020).
Since initial epidemiological data pointed towards COVID-19
specially affecting older patients where diabetes, CV diseases and
obesity are frequent comorbidities, it is under discussion whether
these comorbidities and especially diabetes actually increase the
risk of infection or only the severity or if they are just co-existing
preconditions more frequently found in the severely affected
patients (Ceriello et al., 2020; Fadini et al., 2020).
Pathophysiology of COVID-19: Pulmonar
and Cardiovascular Complications
Acute respiratory distress syndrome (ARDS) is the main death
cause of COVID-19 (Huang et al., 2020). Autopsy and radiography
findings detected acute lung inflammation in patients, characterized
by accumulation of infiltrated leukocytes (Li L. et al., 2020). In fact,
one of the main causes for ARDS is the cytokine storm, that results
in an excessive inflammatory response. Although macrophages doAugust 2020 | Volume 11 | Article 1161
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these cells leads to overproduction of pro‐inflammatory cytokines
potentially leading to acute lung injury (ALI) and ARDS (He et al.,
2006). Besides macrophages, the role of activated endothelial cells is
increasingly acknowledged to be implicated in the inflammatory
response in ARDS (Villar et al., 2019), as alveolar–capillary barrier
disruption is the key determinant for the progression of severe
hypoxemia shown in COVID-19 patients (Li L. et al., 2020). Several
epidemiological studies suggest that type 2 diabetic patients display
increased risk of developing pulmonary hypertension and worse
survival (Kolahian et al., 2019).
Although COVID-19 is primarily acknowledged as a
respiratory disease, lung damage can be attributable to a great
extent to an initial CV cause such as embolism or pulmonary
hypertension. Not only CV complications can be a key cause of
death in COVID-19, but those patients with previous CV diseases
are at increased risk of death (Guo et al., 2020; Zhou et al., 2020).
In fact, CV impairment manifestations are arising as relevant
secondary complications during SARS-CoV-2 infection. On one
hand, it has been observed that previous CV conditions worsen upon
COVID-19 diagnosis (Guo et al., 2020), although cerebrovascular
accidents have intriguingly been also reported in healthy young
patients with no history of chronic conditions (Oxley et al., 2020).
The main CV complications reported in COVID-19 are
myocardial infarction, arrhythmia, stroke and arterial and
venous thromboembolism, including pulmonary embolism
(E S Cardiology, 2020; Wang D. et al., 2020). The ability of
SARS-CoV-2 to directly infect other cells beyond the lung
epithelium causing myocarditis and endothelitis might be the
underlying explanation, but also an exacerbated immune and/or
coagulation response. SARS-CoV-2 can induce, as other SARS-
CoVs, direct damage on the cardiomyocytes, in line to reported
interstitial monoculear inflammatory cells infiltration in the
myocardium of COVID-19 positive patients (Xu et al., 2020).
In fact, cardiac injury has been reported in about 20% of the
analysed patients (Guo et al., 2020; Zhou et al., 2020).
A retrospective case series analysing 187 patients in Wuhan
observed that patients with underlying CV disease were the ones
presenting more severe heart damage, as indicated by elevated
troponin T (TnT) and N-terminal pro-brain natriuretic peptide
(NT-pro-BNP) levels (Chen et al., 2020; Guo et al., 2020). Indeed,
high NT-pro-BNP levels in critially ill patients was also associated
with acute respiratory symptoms and increased inflammatory status
(Yang C. et al., 2020). Equally, patients with no preexisting heart
conditions have shown signs of cardiac damage (Li B. et al., 2020).
Endothelitis was also evidenced by postmortem electron
analysis of viral inclusion structures in renal endothelial cells
(Varga et al., 2020). In fact, SARS-CoV-2 was able to directly
infect engineered human blood vessel organoids in vitro
(Monteil et al., 2020). Accumulated inflammatory cells and
apoptotic bodies near vascular beds (Varga et al., 2020) lead to
altered vascular permeability (E S Cardiology, 2020), an
important sign of endothelial dysfunction. Endothelial
dysfunction is a hallmark of CV disease found in hypertension,
diabetes and obesity. However, SARS-CoV-2 might impair
endothelium functionality not only on those patients withFrontiers in Pharmacology | www.frontiersin.org 3previous weakened vasculature, but also in healthy individuals.
There are case-reports of patients under 50 presenting sudden
strokes even with mild manifestations of COVID-19 onset
(Oxley et al., 2020).
Coagulopathy has been diagnosed in several fatal and non-fatal
cases, with a number of thrombotic parameters altered in COVID-
19 patients, including anti-thrombin activity (AT), pro-thrombin
time (PT) and D-dimer (Wang D. et al., 2020; Zhang D. et al.,
2020). Reported higher D-dimer levels paralleled massive
elevation of pro-coagulant von Willebrand factor and factor
VIII, indicating endothelial activation (Escher et al., 2020).
Endothelial activation leads to chemokine and cytokine release
resulting in recruitment of immune cells, perpetuating and
spreading inflammation to neighbouring tissues. In fact, a
retrospective analysis of the coagulation features in 183 patients
determined that fatal COVID-19 cases displayed disseminated
intravascular coagulation (Tang et al., 2020), which is strictly
linked to endothelial dysfunction and reinforces the sense of
SARS-CoV-2 deteriorating endothelium in the lung and beyond.
Thus, CV complications might represent cause and effect of
pulmonary manifestations of COVID-19. Microvascular
dysfunction of lung capillaries implies the development of
pulmonary oedema due to increased vascular permeability,
which also allows SARS-CoV-2 to invade other vascular beds
(Varga et al., 2020). In the same way, clots coming from
peripheral vessels can migrate to the lungs or even the brain
and cause pulmonary thromboembolism or strokes. In fact,
evidence in both animals and humans has demonstrated that
fibrinolytic therapy in ARDS and ALI improves survival (Wang
J. et al., 2020). Therefore, vascular function preservation in
COVID-19 treatment, and more specifically, in diabetic
patients might improve the disease prognosis.
Angiotensin-converting enzyme-2 (ACE2) is a pivotal protein in
the protecting branch of the renin-angiotensin-aldosterone system
(RAAS), as it metabolizes angiotensin (Ang) II into its physiological
antagonist Ang-(1-7), which oposses its detrimental vascular effects
(Santos et al., 2018). In fact, type 2 diabetic patients display an
umbalanced AngII/Ang-(1-7) ratio (Srivastava et al., 2019).
Analogously, DPP4 upregulation has been associated with
vascular pathophysiology in diabetes and obesity (Röhrborn et al.,
2015; Wronkowitz et al., 2015). We hypothesize that enhanced
circulating levels of soluble DPP4 and misbalanced ACE2
expression found in obesity and T2DM may contribute to the
severity of COVID-19 related to these disease/comorbidities.
Furthermore, due to their vascular effects, both DPP4 and ACE2/
Ang II axis arise as potential therapeutic targets to ARDS and CV
complications in COVID-19 that might be pharmacologically
scoped, as it will be detailed below.MECHANISMS OF SARS-COV-2 ENTRY
INTO HOST CELLS
Similarly to SARS-CoV, it has been proposed that SARS-CoV-2
enters human cells using ACE2 as receptor (Zhang H. et al., 2020).August 2020 | Volume 11 | Article 1161
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the viral spike protein, it is primed by the host serine protease
TMPRSS2, which ultimately allows fusion of viral and cellular
membranes. Although ACE2 is ubiquosly expressed, with higher
expression in theCV system,within the lung it is specifically found in
alveolar epithelial cells and lung endothelial cells (Santos et al., 2018).
In the lung, SARS-CoV infects mainly pneumocytes and
macrophages (Shieh et al., 2005). The peptidases in the lung
epithelium and endothelium have been proposed as primary sites
for coronavirus infection once the viral infection progresses in
the respiratory tract. In this line, it has been suggested that the
use of peptidases by coronaviruses to enter host cells might rely
more on their abundance than on their proteolytic activity (Li
et al., 2003). However, the specific proteins that facilitate SARS-
CoV-2 entry in host cells remain unclear.
It has been suggested that other betacoronavirures require the
participation of diverse surface proteins for human cells invasion.
Thus, sialic acid receptors and C-type lectin receptor CD209/DC-
SIGN, expressed on the surface of macrophages and dendritic cells,
participate in SARS-CoV invasion into immune cells in vivo (Li
et al., 2003; Kuba et al., 2005). In vitro the transmembrane
glycoprotein CD147/basigin has been described to mediate SARS-
CoV invasion. Interestingly, the interaction of CD147 and SARS-
CoV-2 RBD has been observed and successfully prevented by
competitive anti-CD147 treatment (Wang K. et al., 2020).
On the other hand, MERS-CoV binds to human DPP4/CD26
to infect host cells (Raj et al., 2013). A very recent study
predicting the structure of the SARS-CoV-2 spike glycoprotein
and its glycan shield pattern suggests that DPP4/CD26 may also
act as receptor for SARS-CoV-2 (Vankadari and Wilce, 2020). In
favor of this hypothesis lays the highest co-expression of DPP4
with ACE2 (Qi et al., 2020). In fact, unique residues of SARS-
CoV-2 glycoprotein predicted to bind ACE2 can also interact
with DPP4 (Vankadari and Wilce, 2020).
Since MERS-CoV binds to DPP4, a transgenic mouse model
expressing human DPP4 on relevant cells as epithelial and
alveolar pulmonary cells has been used to study the impact of
diabetes on MERS-CoV infection. MERS-CoV-infected diabetic
mice expressing DPP4 suffered more severe symptoms for longer
time than corresponding infected controls (Kulcsar et al., 2019).
Therefore, we hypothesize that DPP4 might represent a link
between diabetes and morbi-mortality/severity of COVID-19.RAAS AND SDPP4 IN DIABETES AND
OTHER COMORBIDITIES
Cardiovascular Effects of ACE-Ang II-
AT1R Axis Upregulation and Ang-(1-7)/
Mas Axis Dowregulation
The RAAS is a key player in the regulation of CV homeostasis in
both health and disease. Ang II is the primary effector of RAAS,
upregulated in the context of vascular pathophysiology exerting
vasoconstrictor, pro-oxidant, pro-inflammatory, pro-fibrotic and
proliferative effects, mostly through AT1 receptors (Romero
et al., 2019). ACE2 is a pivotal protein in the protecting branchFrontiers in Pharmacology | www.frontiersin.org 4of RAAS, as it metabolizes Ang II into Ang-(1-7) and Ang I into
Ang-(1-9) which is in turn metabolized as Ang-(1-7) by
angiotensin-converting enzyme (ACE). Ang-(1-7) opposes to
Ang II-induced detrimental vascular effects participating in
vasodilator, anti-inflammatory, anti-oxidant, anti-proliferative,
anti-thrombotic and anti-senescence responses through Mas
receptors (Santos et al., 2018; Romero et al., 2019). Moreover,
Ang-(1-7) stimulates pleiotropic cytoprotective pathways (Nrf2-
HO-1 axis) (Romero et al., 2019) (Figure 1).
Under physiological conditions, the RAAS peptides are
produced in a balanced manner, whereas misbalance of the
RAAS has been implicated in arterial hypertension and
diabetes. It has been proposed that increased Ang II can
contribute to hyperglycaemia and dyslipidaemia, impairment
of vascular function and inflammation. ACE2 deficiency
increased vascular inflammation and atherosclerosis in ApoE
knockout mice (Thomas et al., 2010). In fact, ACE2-Ang-(1-7)/
Mas axis was shown to participate in the reduction of obesity-
induced inflammation and chronic renal failure (Santos et al.,
2018). In addition, Ang-(1-7) can exert anti-inflammatory effects
over RAAS-independent pro-inflammatory stressors as
interleukin (IL)-1b (Villalobos et al., 2016; Romero et al., 2019).
SARS-CoV spike glycoprotein injection into mice decreased
ACE2 expression levels, worsening lung injury (Kuba et al.,
2005). Similarly, SARS-CoV-2-ACE2 binding induced ACE2
internalization (Zhang H. et al., 2020), resulting in Ang II
accumulat ion and insufficient Ang-(1-7) synthesis .
Importantly, ACE2 is also directly down-regulated by pro-
inflammatory cytokines (Lang et al., 2006). ACE2 serves both
as entry receptor and protective mediator in the lung (Monteil
et al., 2020), in concordance with data observing decreased ACE2
expression and activity in human idiopathic pulmonary fibrosis
(Li et al., 2008). Taking that ACE2 is highly expressed in the
endothelium and heart (Santos et al., 2018), decreased ACE2
levels may also lead to imbalanced RAAS signalling and potential
disruption of CV homeostasis in COVID-19 patients.
Cardiovascular Effects of sDPP4
Upregulation
DPP4/CD26 is a serine protease cleaving a wide variety of
substrates including the incretin hormones glucagon-like peptide
1 (GLP-1) and gastric inhibitory peptide (GIP), cytokines and
growth factors (Röhrborn et al., 2015). DPP4 can be found as a
membrane-bound form or be shedded as a soluble form (sDPP4)
that maintains its enzymatic activity (Röhrborn et al., 2015). We
hypothesize that enhanced circulating sDPP4 may promote
T2DM-related severity of COVID-19.
In the context of obesity and T2DM, both AT and liver have
been proposed as relevant sources of sDPP4 in humans, although
the main source remains under discussion. Our group identified
sDPP4 as a novel adipose-derived factor (Lamers et al., 2011),
whose circulating levels are enhanced in visceral fat from obese
and insulin-resistant patients and correlate with BMI (Sell et al.,
2013). While sDPP4 plasma activity and levels have been
associated with liver apoptosis, fibrosis, fat content, and
NAFLD (Baumeier et al., 2017; Romacho et al., 2020).August 2020 | Volume 11 | Article 1161
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its immunomodulatory activity. Thus, DPP4 triggers T cell
activation, proliferation and cytokine production alone (Focosi
et al., 2020) or through the interaction with immune partners on
antigen presenting cells as CD45, caveolin-1, manose-6
phosphate receptor, or adenosine deaminase (ADA) (Röhrborn
et al., 2015; Williams et al., 2015) (Figure 1). DPP4 expression is
enhanced on blood T lymphocytes from type 2 diabetic patients
and correlates with insulin resistance and glycated hemoglobin
(Lee et al., 2013). sDPP4 treatment enhanced LPS-induced
tumor necrosis factor (TNF)-a and IL-6 secretion in activated
monocytes. Besides its upregulation in T2DM and obesity, DPP4
expression is increased in senescent cells (Kim et al., 2017).
Immunomodulatory effects of DPP4 have been also
demonstrated in animal models. Exogenous injected sDPP4
increased monocyte migration in vivo in a model of low-
density-lipoprotein receptor-deficient mice. Interestingly,
upregulation of DPP4 in obese and diabetic animals have
evidenced also its role on immune responses dysregulation. In
this regard, genetic depletion of DPP4 improved adipose tissue
inflammation in dark agouti rats (Röhrborn et al., 2015;
Romacho et al., 2020).
Some DPP4 substrates with CV impact are upregulated in
obesity and/or T2DM as well as in COVID-19 such as CXCL5/
RANTES and BNP (Niraula et al., 2018; Adela et al., 2019). In
fact, high BNP levels were positively correlated with the
incidence of CV events and mortality in HIV-infected patients,
and was suggested as an indicator of patients condition
deterioration from mild to severe prognosis also in COVID-19
(Yang C. et al., 2020).
DPP4 is also known to interact with extracellular matrix
(ECM) proteins, participating in both cell migration and tissue
remodelling. By binding to fibronectin, DPP4 can promote T cell
helper migration and accummulation in areas with increasedFrontiers in Pharmacology | www.frontiersin.org 5ECM proteins, such as damaged blood vessels (Aroor et al.,
2013). DPP4 also interacts with fibroblast activation protein
(FAP)-a/seprase leading to migration and invasion of
endothelial cells into collagen matrices (Ghersi et al., 2006).
Moreover, stromal cell-derived factor alpha (SDF-1a) is also a
substrate of DPP4, and inhibition of DPP4 has been observed to
increase SDF-1a/CXCR4-induced mobilization of endothelial
cells from bone marrow to injured vascular sites (Aroor
et al., 2013).
Via its interaction with ADA, DPP4 activates plasminogen-2
leading to increased plasmin levels which contributes to
degradation of ECM proteins and the activation of matrix
metalloproteinase (MMP)-4, which facilitates immune cells
migration and diapedesis (Kameoka et al., 1993; Röhrborn
et al., 2015). It has been recently proposed that plasmin among
other proteases may cleave a new furin site in the spike protein of
SARS-CoV-2, leading to an increase in infectivity and severity.
This excess of plasmin may contribute to the hyperfibrionolysis
resulting in enhanced D-dimer in severe patients (Ji et al., 2020).
Importantly, besides its immunomodulatory effects, sDPP4
can exert direct deleterious effects on the vascular wall. sDPP4
directly promoted human smooth muscle cell (hVSMC)
proliferation and inflammation via NF-kB activation resulting
in the upregulation of pro-inflammatory cytokines such as
monocyte chemoattractant protein (MCP)-1, IL-6 and IL-8,
through a novel mechanism mediated by the activation of the
protease activated receptor (PAR)-2 (Wronkowitz et al., 2014).
DPP4 is itself expressed in the vasculature (Zhong et al., 2015). In
hVSMC DPP4 shedding is stimulated by hypoxia in parallel to
MMP-1 expression (Röhrborn et al., 2014). Moreover, PAR2
activation induced by sDPP-4 triggered endothelial dysfunction
in mesenteric microvessels through thromboxane A2 release
mediated by cyclooxygenase (COX) and the thromboxane A2
receptor (TP) activation (Romacho et al., 2016).FIGURE 1 | Diagram summarizing the main physio- and pathophysiological functions of ACE2 and DPP4, their potential contribution to CV complications in COVID-
19 as well as potential therapeutic strategies interfering with these 2 factors to counteract CV complications in COVID-19 and type 2 diabetic patients.August 2020 | Volume 11 | Article 1161
Valencia et al. DPP4 and ACE2 Modulation: To the Heart of COVID-19Thus we hypothesize that DPP4 expression may contribute to
T2DM-related severity of SARS-CoV-2 infection. Furthermore,
due to its vascular effects, sDPP4 arises as a potential contributor
to ARDS severity by potentially inducing inflammation
and bronchoconstriction.THERAPEUTIC POTENTIAL OF RAAS-
TARGETED DRUGS IN DIABETIC
PATIENTS WITH COVID-19
ACEis and ARBs
Despite the initial concerns about ACE inhibitors (ACEi) and AT1
receptor blockers (ARB) treatment potentially predisposing patients
to SARS-CoV-2 infection and/or increased COVID-19 severity, the
European Medicines Agency advised to continue those
prescriptions (EMA/143324/2020; EMA/284513/2020). ACEi/
ARBS are primarily prescribed for treating hypertension and
associated left ventricular dysfunction, employed in about 35% of
the hypertensive population in China (Vaduganathan et al., 2020).
SARS-CoV-2-ACE2 binding leads to ACE2 downregulation and
concomitant misbalance of Ang II/Ang-(1-7) ratio towards Ang II-
induced detrimental effects. Ang II binding to AT1 receptors
increases pulmonary vascular permeability contributing to lung
pathology, as previously shown in relation to SARS-CoV lethality
(Kuba et al., 2005). Some reports observed that ACEi fail to inhibit
ACE2 (Turner et al., 2002) and suggested that small peptide specific
ACE2 inhibitors as DX600 as more efficient inhibiting SARS-CoV
cell entry in vitro (Guy et al., 2005). Nevertheless, ACEi or AT1R
may induce ACE2 upregulation as detected both in animal models
at mRNA and protein level (Sukumaran et al., 2011), as well as
urinary excretion in olmesartan-treated hypertensive patients
(Furuhashi et al., 2015). Taking that increased ACE2 expression
also leads to increased Ang-(1-7) production, chronic ACEi and
ARB may protect COVID-19 patients. A former study showed that
ARB prevented ALI damage in SARS-CoV-infected mice (Kuba
et al., 2005). Accordingly, previous studies have shown that ACEi
treatment is associated with a diminished risk of pneumonia in both
type 1 and type 2 diabetic patients (van de Garde et al., 2007).
In this line, recent studies have demonstrated that the risk of
severe COVID-19 was decreased in patients taking ARB in
comparison to no-hypertensive patients (Lu et al., 2020; Meng
et al., 2020). Interestingly, ACEi/ARB-treated COVID-19
positive patients displayed lower concentrations of CRP and
procalcitonin (Yang G. et al., 2020), suggesting that the benefit of
ACEi and ARB might rely on their anti-inflammatory effects.
Indeed, ARB treatment in rats reduced plasma TNF-a, IL-1b and
IL-6 levels and increase IL-10 (Simões e Silva et al., 2013). The
ongoing clinical trial BRACE-CORONA (NCT04364893) will
compare the impact of temporary discontinuation of ACEi or
ARB on mortality and days of hospital stay on patients with
SARS-CoV-2 infection (Lopes et al., 2020).
Ang-(1-7) Analogues
Restoring the balance between the RAAS peptides may be an
efficient pharmacological approach against COVID-19. The lossFrontiers in Pharmacology | www.frontiersin.org 6of protective Ang-(1-7) as a result of reduced ACE2 availability,
may exaggerate the hyper-inflammatory environment in the lung
and beyond. Ang-(1-7) supplementation may reveal as an effective
pharmacological strategy to attenuate severe CV complications in
COVID-19, as we have recently hypothesized (Peiró and Moncada,
2020). In animal models of ALI and ARDS, Ang-(1-7) has
demonstrated anti-inflammatory and anti-fibrotic effects via, at
least in part, the G protein-coupled receptor Mas (Klein et al.,
2013; Santos et al., 2018). Accordingly, administration of Ang-(1-7)
and its synthetic analogue AVE 00991 have been reported to reduce
leukocyte adhesion to the microvascular endothelium in a model of
arthritis (Simões e Silva et al., 2013).
Indeed, the COVID-ARA2 (NCT04337190) and ATCO
clinical trial (NCT04332666) will evaluate Ang II blockade and
Ang-(1-7) supplementation in the context of lung disease in
COVID-19 patients.
rhACE2 as Decoy Factor
It has been demonstrated that recombinant human ACE2
(rhACE2), already tested in phase 2 clinical trials for
ARDS/ALI treatment (NCT01597635), blocks SARS-CoV-2
infection in Vero cells and binding to both human blood
vessels and human kidney organoids (Monteil et al., 2020).
Indeed, the recombinant sACE2 drug will be used in an
interventional clinical trial over 200 COVID-19 patients
(APN01-COVID-19, NCT04335136).
However, rhACE2 has been suggested not only to hamper
SARS-CoV-2 entry into host cells but also potentially to protect
from lung injury and vascular dysfunction. ACE2 administration
lowered blood pressure and improved endothelial function in an
Ang-(1-7)-mediated manner in a model of spontaneously
hypertensive stroke-prone rats (SHSPR) (Focosi et al., 2020).
In this line, direct activation of ACE2 by NCP-2454 improved
pulmonary arterial compliance in a model of pulmonary
hypertension (Haga et al., 2015). Moreover, administration of
rhACE2 normalized Ang II levels in isolated human hearts with
dilated cardiomyopathy (Basu et al., 2017).THERAPEUTIC POTENTIAL OF
TARGETING DPP4 IN DIABETIC
PATIENTS WITH COVID-19
Gliptins
During COVID-19 infection vascular functionality is endangered.
Therefore, preservation of vascular integrity might be a key
priority. In case DPP4 represents a link between diabetes and
the severity of COVID-19, DPP4i may hold additional therapeutic
value to protect diabetic patients suffering COVID-19, as recently
especulated (Drucker, 2020; Iacobellis, 2020).
DPP4i, the so-called gliptins, are antidiabetic drugs based on
the control of glucose homeostasis through inhibition of DPP4
enzymatic activity. DPP4 cleaves and inactivates the incretin
hormones GLP-1 and GIP, which account for up to 60–70% of
postprandial insulin release. This way DPP4i prolong the half life
of incretins. Besides its action on incretins, gliptins have beenAugust 2020 | Volume 11 | Article 1161
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Regarding DPP4 inhibition as a therapeutic strategy to treat and
prevent CV diseases in obese and/or type 2 diabetic patients
there is still an ongoing discussion. Importantly, gliptins are
preferred as add-on therapy in individuals with diabetes coursing
with previous chronic kidney disease or additional CV disease
(Hanssen and Jandeleit-Dahm, 2019).
CV safety of gliptins has been confirmed in several CV
outcome trials (SAVOR TIMI 53, NCT01107886; EXAMINE,
NCT00968708; TECOS, NCT00790205; CARMELINA,
NCT01897532). In relation to their glycemic action, gliptins
have demonstrated no risk of hypoglycemic episodes, neutral
influence on body weight and a significant reduction of glycated
hemoglobin levels (HbA1c), which are important factors
associated with reduced CV risk and mortality (Zoungas et al.,
2010). Moreover, DPP4i have positive effects over surrogate
vascular endpoints, namely blood pressure, lipemia and
endothelial function, albeit these CV outcome trials failed in
demonstrating additional benefits of gliptins on major CV events
(Scheen, 2018). However, gliptins are widely used as T2DM
treatment. It has been shown that combined metfomin and
gliptin therapy significantly decreased the relative risk of non-
fatal CV events, CV mortality and all-cause mortality, in
comparison to other oral antihyperglycemic drugs as
sulfonylureas (Wang et al., 2017).
Preclinical studies have shed light on the mechanisms by which
gliptins might improve CV functionality. Increased bioavailability of
substrates of DPP4 such as GLP-1 confers indirect cardioprotective
effects to gliptins. Beyond GLP-1, DPP4 inhibition increases the
effects of other substrates with cardiovascular impact. T2DM
patients trated with sitagliptin displayed higher SDF-1a plasma
levels resulting in increased endothelial progenitor cells (EPCs),
which play a key role in vascular repair (Fadini et al., 2010). In vitro,
SDF-1a was also able to improve blood flow in a model of
peripheral artery disease (Segers et al., 2011). Equally, an increase
in BNP improved the regulation of natriuresis and the vasodilatory
responses (Brandt et al., 2006).
In our hands, both hVSMC proliferation and inflammation as
well as ex vivo endothelial dysfunction exerted by sDPP4 were
equally prevented by the experimental and clinically available
DPP4i K579 and linagliptin, respectively (Wronkowitz et al.,
2014; Romacho et al., 2016) That suggests that these drugs may
add CV benefit beyond regulating glucose homeostasis and in a
GLP-1-independent manner.
In animal models of diabetes, gliptins have also proven
protective effects. Vildagliptin-treated streptozotocin (STZ)-
induced diabetic rats presented reduced oxydative stress and
ICAM-1 and plasminogen activator inhibitor type-1 (PAI-1)
expression (Maeda et al., 2012). In db/db mice linagliptin
improved cardiac dysfunction by reducing the activation of
the Nlrp3/ASC inflammasome and the upregulation of
collagen-1 and collagen-3 (Birnbaum et al., 2019). Similarly,
sitagliptin also improved cardiac function in mice (Picatoste
et al., 2013). Anti-oxidant properties of DPP4i have been also
shown under acute inflammation in a mouse model of LPS-
induced sepsis (Beckers et al., 2017).Frontiers in Pharmacology | www.frontiersin.org 7In type 2 diabetic patients, sitagliptin treatment reduced the
molecular markers of inflammation as CRP and IL-6 in
mononuclear cells (Makdissi et al., 2012), as well as circulating
levels of TNF-a, IL-1b, IL-6, intracellular adhesion molecules
and CRP (Tremblay et al., 2014). Sitagliptin also impoved the
flow-mediated vasodilation in diabetic adults (Barchetta et al.,
2019). Importantly, sitaglipitin conferred cardioprotection in
diabetic patients with chronic kidney disease (CKD) reducing
the Ang II/Ang-(1-7) ratio (Beraldo et al., 2019).
Gliptins can preserve endothelial function by their reported
anti-inflammatory, anti-oxidant and potentially protective effects
on the vascular system (Avogaro and Fadini, 2018), which are
beneficial aspects in the fight against COVID-19. Additionally, a
meta-analysis of large randomized clinical trials demonstrated
that gliptin treatment did not increase the risk of general
infections in type 2 diabetic patients (Yang et al., 2016).
Besides offering potential CV protection, gliptins might be
also employed to restrain SARS-CoV-2 binding to host cells.
DPP4i ability to hamper coronavirus entry to host cells has been
studied. Sitagliptin, vildagliptin or saxagliptin could not block
MERS-CoV access to Vero cells (Raj et al., 2013). Contrarily,
sitagliptin was able to hamper MERS-CoV infection in
macrophages by reversing the immunosuppressive capacity of
the virus (Al-Qahtani et al., 2017).
All approved gliptins are competitive reversible inhibitors of
DPP4 enzymatic activity (Deacon, 2011). However, gliptins can be
categorized in 3 classes based on the subsites within the DPP4
molecule they occupy. Class 1 comprises peptidomimetic DPP4i
with the most basic binding to DPP4 such as vildagliptin and
saxagliptin.While class 2 inhibitors (alogliptin and linagliptin) and
class 3 inhibitors (sitagliptin and teneligliptin) display an increased
number of interacting points. The more interacting points the
higher inhibitory potency (Nabeno et al., 2013). DPP4
extracelullar structure consists of two domains comprised of a
eight g-bladded b-propeller domain and a C-terminal a,b-
hydrolase domain with the catallytic triad (Asp708, His740,
Ser630) (Röhrborn et al., 2015). Conserved aminoacids on DPP4
catalytic site are displayed in pockets S1 and S2. However, the
catalytic pocket does not colocalize with the proposed binding sites
of SARS-CoV-2 to DPP4 (Vankadari and Wilce, 2020).
Nevertheless, previous structural studies regarding MERS-CoV-
DPP4 interaction demonstrated that residues in the b-propeller
domain of DPP4 (Arg54–Asn497) were essential for virus S1
glycoprotein binding, and some of them are also shared by SARS-
CoV-2 (Vankadari and Wilce, 2020).
The residue Asp542 was ascertained as a binding point of
SARS-CoV-2 to DPP4, as it was also demonstrated for MERS-
CoV (Vankadari and Wilce, 2020). Interestingly, class 1 and 2
gliptins (saxagliptin, alogiptin and linagliptin) are able to bind
near this residue (Tyr547) in a zone beyond DPP4 pockets S1
and S2 called S1’ subsite (Nabeno et al., 2013). Uracil ring of
alogliptin and linagliptin cause a conformational change on
DPP4 S1’ subsite hampering its enzymatic activity (Nabeno
et al., 2013). Therefore, this type of xhantine-based non-
peptidomimetic gliptins could potentially impair SARS-CoV-2
binding to one of its preferred sites in DPP4. In addition,August 2020 | Volume 11 | Article 1161
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predicted to bind ACE2 with same or even better binding
energy than they have for DPP4 (Abouelkheir and El-
Metwally, 2019), suggesting additional benefit as SARS-CoV-2
therapy. Whether if more complex class 3 gliptins could exert a
steric hindrance to SARS-CoV-2 acess into DPP4 needs further
investigation. In this line, a very recent approved clinical trial
SIDIACO (NCT 04365517) will study the clinical response of
T2DM patients with COVID-19 treated with sitagliptin.
DPP4 immunomodulatory function raises the question whether
DPP4i might alter the immune response in diabetic patients (Shao
et al., 2020). The pharmakokinetic and pharmacodynamic
properties of DPP4i allow that DPP4 enzymatic activity in
tissues and circulation is not completey blocked (Drucker, 2020).
Both DPP4 inhibition with des-fluro sitagliptin and genetic
deletion of DPP4 in mice did not alter T-cell dependent immune
responses (Vora et al., 2009). Sitagliptin, vildagliptin and
saxagliptin did not alter innate immune response triggered by
Toll-like receptor (TLR) activation in terms of secretion, co-
stimulation, T cell proliferation and migration in human cells in
vitro and in mice in vivo (Bergman et al., 2006).
An initial meta-analysis reported that although DPP4i is not
associated with an increased risk for respiratory infections they
could increase the risk of urinary tract and nasopharyngitis
infection (Amori et al., 2007). A more recent meta-analysis
assessing the impact of long term use of sitagliptin in T2DM
patients determined that there was not an enhanced risk of
infection (Gooßen and Gräber, 2012). Another study compared
the risk of respiratory tract infections among glucose-lowering
therapies and found no increased risk linked to DPP4i in T2DM
patients (Gamble et al., 2018). However the potential induction of
leucopenia (Pitocco et al., 2010), angioedema (Gosmanov and
Fontenot, 2009) or cough in asthma (Baraniuk and Jamieson,
2010) by DPP4i represent potential pitfalls to their use as therapy
in COVID-19 (Pitocco et al., 2020). Although 14 years after the
approval of DPP4i there have not beenmajor safety issues related to
long term use of gliptins. Nevertheless further clinical research will
help determine if DPP4i can affect infection risk, T cell development
and immune homeostasis in T2DM (Klemann et al., 2016).
sDPP4 as Soluble Decoy Factor
Exogenous administration of sDPP4 inhibited MERS-CoV
infection in VERO cells (Raj et al., 2013). Therefore, in case it
is demonstarted that SARS-CoV-2 can bind DPP4, exogenous
acute administration of sDPP4 as a decoy factor to compete for
binding of the virus to endogenous DPP4 in COVID-19 target
tissues could be explored.
sDPP4 load benefit might not only rely on virus trapping but
also on the blockade of detrimental pathways affecting/worsening
immune responses and importantly, to potentially prevent COVID-
19 effects on the vasculature. In this line, exogenous administration
of sDPP4 was effective to bind to ADA and prevent the formation
of endogenous DPP4/CD26-ADA complex in human dendritic
cells/macrophages resulting in impeded activation and proliferation
of T-cells in vitro (Zhong et al., 2013). Disruption of RANTES/
CCL5-CCR5 axis with the anti-CCR5 antibody leronlimab reducedFrontiers in Pharmacology | www.frontiersin.org 8IL-6 plasma leves and plasma viral load in COVID-19 patients
(Patterson et al., 2020). It has been proposed that sDPP4 may
directly truncate CCL5/RANTES impeding its union to CCR5
(Iwata et al., 1999) therefore sDPP4 may potentially cause the
same effect as leronlimab treatment, leading to an improved
immune response and reduced cytokine storm.
In the case of diabetic patients where significantly increased
sDPP4 plasma concentration are already present (Sell et al.,
2013), the potential risk-benefit of exogenous administration of
sDPP4 as decoy factor should be carefully investigated.
Anti-DPP4 Vaccine
Another therapeutic approach proven succcesful to regulate
plasma DPP4 activity in mice is anti-DPP4 vaccination. Anti-
DPP4 vaccine did not cause any side effect on immune cell
activation nor immune-mediated attack towards DPP4-
expressing cells or tissues. Furthermore it was able to reach
comparable effects to gliptin treatment in regard to glycaemia
control and GLP-1 plasma levels in mice models of both type 1
and type 2 diabetes (Pang et al., 2014; Li et al., 2017). In this line, a
humanized IgG1 monoclonal antibody (YS110) with high affinity
for CD26 was evaluated in a phase I clinical trial, with
demonstrated no effect on T-cell proliferation and cytokine
production in vitro on human CD26-positive lymphocytes
(Angevin et al., 2017). Interestingly, YS110 also inhibited MERS-
CoV infection (Ohnuma et al., 2013). However, it has been
discussed that in vivo administration of anti-DPP4 antibodies
could neutralize plasma sDPP4 before it can coate cellular DPP4
and impede virus entry. In this situation, intranasal application of
sDPP4 or anti-DPP4 antibodies has been presented as a plausible
solution to overcome such effects (Xia et al., 2014).
On the other hand, DPP4/CD26-related signaling was
successfully blocked by the soluble fusion protein Caveolin-Ig,
which demonstrated additional immunosuppresive effects
(Ohnuma et al., 2009). Tissue-factor pathway inhibitor (TFPI)
is a biological blocker of DPP4. Morever, due to its anticoagulant
properties (Mast, 2016), TFPI could be seen as a positive aspect
in the context of COVID-19 treatment, albeit potential clinical
applications have to be carefully evaluted due to its reported role
in cancer (Fei et al., 2017).COMBINED THERAPEUTIC POTENTIAL
TARGETING RAAS AND DPP4
DPP4 signalling and RAAS dysregulation bidirectional crosstalk
has been proposed previously. Ang II was able to induce DPP4
activity in vitro and in vivo (Aroor et al., 2016). Equally, DPP4
inhibition counteracted RAAS overestimulation in a model of
renal ablated rats, where sitagliptin treatment increased Ang-(1-
7) and ACE2 expression and activity and reduced AT1 receptor
expression and Ang II levels (Beraldo et al., 2019). Thus it has
been proposed that DPP4i can attenuate the progression of CV
disease by opposing RAAS negative effects.
ACE2 and DPP4 present common features as endopeptidases
even sharing a wide variety of experimental inhibitorsAugust 2020 | Volume 11 | Article 1161
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combining inhibitory properties of ACEi and DPP4i against
COVID-19 could be appealing. However, it has been observed
that DPP4i therapy, when combined with high-dose ACEi, could
counter the blood pressure lowering effect of ACEi (Aroor et al.,
2013). Combination of ACEi and DPP4i seems unreasonable due
to reported production of angioedema upon coadministration
(Brown et al., 2009). Angioedema is a potentially fatal adverse
reaction as characteristic swelling is generally located around face
and neck endangering block of upper airways. Both proteases
ACE2 and DPP4 have the capacity to proteolyze bradykinin and
substance P leading to accumulation of such vasoactive kinins
inducing vasodilatation and increase in vascular permeability
(Brown et al., 2009). Contrarily, single ACEi or gliptin-associated
angioedema is rare (0.1–0.7%) and in some cases disappeared after
changing to a different type in the same drug class.
On the other hand, it has been suggested that combination of
ARB and DPP4i holds a more effectve therapy for the
management of hypertension, renal function and glycaemic
control in T2DM (Aroor et al., 2013). The combination of
linagliptin and telmisartan induce sinergistic protective effects in
the CV functionality of nephrectomized rats (Beraldo et al., 2019).
Therefore, against SARS-CoV-2 the combination of virus
entry blockers (ACEi or DPP4i) and virus capturing decoy
factors (rhACE2, sDPP4) would be a better option. However,Frontiers in Pharmacology | www.frontiersin.org 9new perspectives into de design of multitarget drugs holds an
important therapeutic oportunity as demonstrated by the
synthesis of an enalapril-sitagliptin merged compound, which
exhibited dual inhibitiory action against human ACE and DPP4
(Abouelkheir and El-Metwally, 2019), with expected reduced
drug-drug interactions and undesirable side effects. Moreover, a
milk-derived heptapeptide was found to bind and inhibit both
ACE and DPP4 activity (Ashok et al., 2019).CONCLUSION
Obese and type 2 diabetic patients are at higher risk of SARS-
CoV-2 severity since both conditions favour CV complications
per se. Therefore, in the meantime vaccines are being developed
and anti-viral drugs are investigated, therapeutic strategies to
fight COVID-19-induced CV alterations are urgently needed.
It is well known that in T2DM and the metabolic syndrome
there is a counterbalance in the RAAS system. Therefore,
strategies aiming to regulate this counterbalance may be a
useful pharmacological strategy to prevent endothelial cell
activation and lung damage in COVID-19 (Table 1). Some
studies suggest that ARB and ACEi may also contribute to
increase Ang-(1-7) and reduce the risk of severity of COVID-
19. Another potential strategy is to provide direct Ang-(1-7)TABLE 1 | Summarized effects of RAAS-targeted drugs (ACEi, ARBS, Ang-(1-7) analogues and rhACE2) reported in preclinical (in vivo and ex vivo) and clinical
research.
Preclinical data Previous clinical trials COVID-19




entry (Guy et al., 2005)
• Prevention of ALI in SARS-CoV-
infected mice (Kuba et al., 2005)
• Cardiac protection: ACE2 and
Ang-(1-7) increase in autoimmune
myocarditis in rats (Sukumaran
et al., 2011)
• Increased ACE2 and
Ang-(1-7) in hypertensive
patients (Furuhashi et al.,
2015)
• Reduced risk of pneumonia
in type 1 and type 2 diabetic
patients (van de Garde et al.,
2007)
• Diminished risk of severe COVID-19
in ARB-treated patients (Meng et al.,
2020)
• Lower concentrations of CRP and
procalcitonin in ACEi/ARB treated
patients (Yang G. et al., 2020)








and cytoprotective effects as
anti- inflammatory, -oxidant,
-proliferative, -thrombotic,
-senescent (Santos et al.,
2018; Romero et al., 2019)
• Anti-inflammatory and anti-fibrotic
effects in ALI and ARDS models
(Klein et al., 2013; Santos et al.,
2018)
• Prevention of cardiac fibrosis in
SD rats (Grobe et al., 2007)
• Impaired leukocyte adhesion to
microvascular endothelium in
arthritis (Simões e Silva et al.,
2013)
• ATCO (NCT04332666)
• TXA127 COVID (NCT04401423)
• NCT04375124 (Ang-(1-7) vaccine)
rhACE2 • Block SARS-CoV-2 infection
in Vero cells, human blood
vessels and kidney organoids
(Monteil et al., 2020)
• Recovered Ang II levels in
human isolated hearts (Basu
et al., 2017)
• Blood pressure decrease and
improved endothelial function in
SHSRP rats (Focosi et al., 2020)
• Improved pulmonary arterial
compliance in pulmonary
hypertension (Haga et al., 2015)
• Phase II clinical trial for
ARDS/ALI (NCT01597635)
• APN01-COVID-19 (NCT04335136)
• Bacterial ACE2 (NCT04375046)August 2020 | Volume 11 | Article 1161
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complications in COVID-19 as recently published by us (Peiró and
Moncada, 2020). The role of ACE2 as SARS-CoV-2 receptor, may
lead to reduced ACE2 availability and potentially resulting in
hyperinflammation. The use of rhACE2 as decoy receptor
deserves further investigation.
Similarly, in the case it is confirmed that DPP4 plays a role in
SARS-CoV-2 infection as co-receptor, the use of sDPP4 as decoy
receptor could also be explored. However, in obesity and T2DM
sDPP4 levels are upregulated, sDPP4-induced immunomodulatory
actions might be altered and there is a reduced bioavailability of
beneficial substrates, facing COVID-19 CV consequences might be
a difficult task. Other potential therapeutic approaches worth
exploring are DPP4i in order to determine if they can block
virus entry, as described for sitagliptin in MERS. Irregardless of
DPP4 role as co-receptor, gliptins might help prevent CV
complications in COVID-19 due to their anti-inflammatory
effects at vascular level. Anti-DPP4 vaccine has been proven
effective in mice to control glucose homeostasis and might
represent another potential approach.
In conclusion, further preclinical research and clinical data
will help to better understanding of the SARS-CoV-2 virusFrontiers in Pharmacology | www.frontiersin.org 10(Table 2), and will allow to determine if any of these potential
therapeutic strategies is useful.AUTHOR CONTRIBUTIONS
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Preclinical data Previous clinical trials COVID-19
Cells Animal models Ongoing clinical trials
Gliptins • Block MERS-CoV infection in
macrophages (Al-Qahtani et al.,
2017)
• Prevention of sDPP4-induced
hVSMC proliferation and




dysfunction in mice (Romacho
et al., 2016)
• Anti-oxidant effects in
STZ-induced diabetic rats and
LPS-induced sepsis mouse
model, respectively (Maeda et al.,
2012; Beckers et al., 2017)
• Reduction of
NLRP3/ASC inflammasome
activation in db/db mice
(Birnbaum et al., 2019)
• Improved cardiac function in mice
(Picatoste et al., 2013)
• Decreased risk of non-fatal CV events
and CV mortality (Wang et al., 2017)
• No risk of infection in type 1 and type 2
diabetic patients (Yang et al., 2016)
• Increased cardio and vasculoprotective
substrates (Brandt et al., 2006; Segers
et al., 2011; Fadini et al., 2020)
• Anti-inflammatory effects in type 2 dibatec
patients (Makdissi et al., 2012; Tremblay
et al., 2014)
• Improved flow-mediated vasodilation in
diabetic patients (Barchetta et al., 2019)
• Potential induction of
leucopenia, angioedema, cough and
asthma (Gosmanov and Fontenot, 2009;







sDPP4 • Block MERS-CoV infection in





effects (Wronkowitz et al., 2014;
Romacho et al., 2016)
• Inhibition of T-cell activation and
proliferation via ADA binding
(Zhong et al., 2013)
• Endothelial dysfunction in murine
mesenteric microvessels
(Romacho et al., 2016)
• Increased monocyte migration in
LDLR-/- mice (Sha et al., 2014)
• Direct truncation of
CCL5/RANTES: reduced
IL-6 levels and viremia
(Iwata et al., 1999;







• No effects on T-cell proliferation
or cytokine production (Angevin
et al., 2017)
• Increased GLP-1 in type 1 and
type 2 diabetic mice (Pang et al.,
2014; Li et al., 2017)August 2020 | Volume 11 | Article 1161
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